Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration (L2-267)

European Institute of Oncology

Status: Enrolling

Conditions: Metastatic Prostate Cancer (mPC)

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06762379

L2-267

Details and patient eligibility

About

Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration

Full description

Analysis of the current clinical landscape of mPC Italy to identify gaps and opportunities for improvement.

Patient identification and enrollment Blood sample collection and plasma purification ctDNA extraction and NGS analysis of homologous recombination repair (HRR) genes. Clinical Real-World Data (RWD) and molecular analysis data collection Testing algorithm development based on collected data Finalization and sharing of a best practice model for diagnostic procedures in mPC patients

Enrollment: 125 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.

Exclusion criteria

• Unable to provide written informed consent

Trial design

125 participants in 1 patient group

patient with metastatic prostate cancer (mPC)